Clinical and Pathologic Characteristics and Outcome of 23 Patients with IBC
| Characteristic | Overall population | pCR group | Non-pCR group |
| Patients (n) | 23 | 5 (22%) | 18 (78%) |
| Age (y) | |||
| Mean ± SD | 51 ± 12.7 | 50.6 ± 9.9 | 52.2 ± 13.3 |
| Range | 34−78 | 37–60 | 34–78 |
| Histology | |||
| Invasive ductal carcinoma | 22 (95%) | 4 (80%) | 18 (100%) |
| Metaplastic carcinoma | 1 (5%) | 1 (20%) | |
| Elston–Ellis grade | |||
| I | 2 (9%) | 2 (11%) | |
| II | 7 (30%) | 7 (39%) | |
| III | 14 (61%) | 5 (100%) | 9 (50%) |
| HR status | |||
| Positive | 11 (43%) | 1 (20%) | 10 (55%) |
| Negative | 12 (57%) | 4 (80%) | 8 (45%) |
| HER2 receptor status | |||
| Positive | 5 (22%) | 2 (40%) | 3 (17%) |
| Negative | 18 (78%) | 3 (60%) | 15 (83%) |
| Triple-negative cancer | 7 (30%) | 2 (40%) | 5 (28%) |
| Ki-67 | |||
| <25% | 7 (30%) | 1 (20%) | 6 (33%) |
| ≥25% | 14 (61%) | 4 (80%) | 10 (55%) |
| Unknown | 2 (9%) | 2 (12%) | |
| NACT | |||
| Anthracycline alone | 14 (61%) | 4 (80%) | 10 (55%) |
| Anthracycline and docetaxel | 9 (39%) | 1 (20%) | 8 (45%) |
| Clinical response | |||
| Complete response | 5 (22%) | 3 (60%) | 2 (11%) |
| Partial response | 15 (65%) | 2 (40%) | 13 (72%) |
| Stable disease | 3 (13%) | 3 (17%) | |
| Survival parameters (mo) | |||
| DMFS (distant metastasis-free survival) | 52.6 | 46 | 54 |
| Overall survival | 73.9 | 79.5 | 72.4 |